Nanjing Pharmaceutical Group Company Limited (SHA:600713)

SHA:600713 Revenue

Nanjing Pharmaceutical Group Company had revenue of 13.98B CNY in the quarter ending June 30, 2026, with 1.88% growth. This brings the company's total for the last twelve months to 54.82B, up 0.71% year-over-year. In the year 2025, Nanjing Pharmaceutical Group Company had annual revenue of 54.96B with 2.36% growth. That makes Nanjing Pharmaceutical Group Company the 1,746th largest company in the world by revenue and 183rd in China.

• Revenue (ttm): 54.82B
• Revenue Growth: +0.71%
• P/S Ratio: 0.12
• Revenue / Employee: 11.67M
• Employees: 4,697
• Market Cap: 6.53B

Revenue Chart

Chart

Chart

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	54.96B	1.27B	2.36%
Dec 31, 2024	53.70B	106.51M	0.20%
Dec 31, 2023	53.59B	3.37B	6.71%
Dec 31, 2022	50.22B	5.10B	11.30%
Dec 31, 2021	45.12B	5.31B	13.33%

Data Source: S&P Global Market Intelligence Last updated: Aug 29, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Oct 25, 2026

Data Sources Report a data error